{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:53:08Z","timestamp":1791175988346,"version":"4.1.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Inflammatory gastrointestinal disease is a common manifestation of inborn errors of immunity (IEI) and may affect any segment of the gastrointestinal tract. Vedolizumab, a gut-selective anti-integrin approved for inflammatory bowel disease, has been scarcely studied in IEI. We describe our experience with vedolizumab in adults with immunodeficiency-associated enteropathy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective case series of adults with humoral or combined immunodeficiency and inflammatory gastrointestinal disease treated with vedolizumab at a single tertiary referral center. Clinical, endoscopic, laboratory and histopathological responses were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Four adult patients with immunodeficiency-associated enteropathy received vedolizumab. Two patients achieved sustained clinical and endoscopic\/histological remission, both of whom had predominant villous atrophy (one with TRAF3 haploinsufficiency, and the other had multiple autoimmune manifestations, refractory immune thrombocytopenia and agammaglobulinemia following rituximab). Another patient with combined immunodeficiency and protein-losing enteropathy had marked clinical improvement with mild histologic response, but relapsed at two years in the setting of norovirus and Clostridium difficile infection. In contrast, a woman with common variable immunodeficiency, autoimmune hepatitis, and severe refractory pancolitis failed to respond to vedolizumab and subsequently developed CMV superinfection, requiring treatment escalation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this case series, vedolizumab was associated with clinical improvement predominantly in patients with villous atrophy rather than refractory colitis. These findings are hypothesis-generating and support further evaluation of vedolizumab as a therapeutic option for selected patients with immunodeficiency-associated enteropathy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1953966","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:36:48Z","timestamp":1791175008000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Vedolizumab treatment in adults with immunodeficiency-associated enteropathy: a case series"],"prefix":"10.3389","volume":"17","author":[{"given":"Ernestina","family":"Angarola","sequence":"first","affiliation":[{"name":"Immunology Section, Hospital Italiano de Buenos Aires","place":["Buenos Aires, Argentina"]},{"name":"Internal Medicine Department, Hospital Italiano de Buenos Aires","place":["Buenos Aires, Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Josefina","family":"Etchevers","sequence":"additional","affiliation":[{"name":"Gastroenterology Section, Hospital Italiano de Buenos Aires","place":["Buenos Aires, Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Andres","family":"De Paula","sequence":"additional","affiliation":[{"name":"Gastroenterology Section, Hospital Italiano de Buenos Aires","place":["Buenos Aires, Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Florencia","family":"Sanchez","sequence":"additional","affiliation":[{"name":"Pathology Department, Hospital Italiano de Buenos Aires","place":["Buenos Aires, Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"Santino","sequence":"additional","affiliation":[{"name":"Pathology Department, Hospital Italiano de Buenos Aires","place":["Buenos Aires, Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Liberatore","sequence":"additional","affiliation":[{"name":"Immunology Section, Hospital Italiano de Buenos Aires","place":["Buenos Aires, Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.70962\/jhi.20250003","article-title":"Human inborn errors of immunity: 2024 update on the classification from the International Union of Immunological Societies Expert Committee","volume":"1","author":"Poli","year":"2025","journal-title":"J Hum Immun"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.02.024","article-title":"Diagnosis and treatment of gastrointestinal disorders in patients with primary immunodeficiency","volume":"11","author":"Agarwal","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.698721","article-title":"Needs for increased awareness of gastrointestinal manifestations in patients with human inborn errors of immunity","volume":"12","author":"Kim","year":"2021","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1026511","article-title":"Understanding inborn errors of immunity: A lens into the pathophysiology of monogenic inflammatory bowel disease","volume":"13","author":"Ouahed","year":"2022","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108362","article-title":"Vedolizumab therapy in common variable immune deficiency associated enteropathy: A case series","volume":"212","author":"Sifers","year":"2020","journal-title":"Clin Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1201\/9781003526827","article-title":"Emerging treatment options in mild to moderate ulcerative colitis","volume":"11","author":"Lichtenstein","year":"2015","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1038\/ajg.2017.246","article-title":"Vedolizumab in patients with common variable immune deficiency and gut inflammation","volume":"112","author":"Boland","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaa012","article-title":"Vedolizumab induced clinical, endoscopic, and histological improvement in common variable immunodeficiency disease-associated intestinal enteropathy","volume":"26","author":"Akhtar","year":"2020","journal-title":"Inflammation Bowel Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.214","article-title":"The enteropathy associated with common variable immunodeficiency: the delineated frontiers with celiac disease","volume":"105","author":"Malamut","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1209570","article-title":"Characterization of infectious and non-infectious gastrointestinal disease in common variable immunodeficiency: analysis of 114 patient cohort","volume":"14","author":"Sanchez","year":"2023","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00149","article-title":"Non-infectious complications of common variable immunodeficiency: Updated clinical spectrum, sequelae, and insights to pathogenesis","volume":"11","author":"Ho","year":"2020","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"997","DOI":"10.2147\/jaa.s418996","article-title":"Chronic diarrhea with villous blunting of the small intestine under capsule endoscopy in common variable immunodeficiency and X-linked agammaglobulinemia: A case series","volume":"16","author":"Deng","year":"2023","journal-title":"J Asthma Allergy"},{"key":"B13","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/apt.14550","article-title":"Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease","volume":"47","author":"Barr\u00e9","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01700","article-title":"Effects of anti-integrin treatment with vedolizumab on immune pathways and cytokines in inflammatory bowel diseases","volume":"9","author":"Rath","year":"2018","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/ibd\/izab117","article-title":"Response to anti-\u03b14\u03b27 blockade in patients with ulcerative colitis is associated with distinct mucosal gene expression profiles at baseline","volume":"28","author":"Gazouli","year":"2022","journal-title":"Inflammation Bowel Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s40425-018-0461-4","article-title":"Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study","volume":"6","author":"Abu-Sbeih","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2024.00190","article-title":"Inflammatory bowel disease in a young female patient with a novel de novo TRAF3 frameshift variant responsive to ustekinumab: a case report","volume":"24","author":"Takeuchi","year":"2025","journal-title":"Intest Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.12890\/2020_001288","article-title":"Fever during anti-integrin therapy: New immunodeficiency","volume":"7","author":"Bonfanti","year":"2020","journal-title":"Eur J Case Rep Intern Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjz108","article-title":"Comment on: \u2018Resolution of CMV infection in the bowel on vedolizumab therapy\u2019","volume":"14","author":"Hommel","year":"2020","journal-title":"J Crohns Colitis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjz033","article-title":"Resolution of CMV infection in the bowel on vedolizumab therapy","volume":"13","author":"Rawa-Go\u0142\u0119biewska","year":"2019","journal-title":"J Crohns Colitis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12884","article-title":"Chronic norovirus infection and common variable immunodeficiency","volume":"188","author":"Woodward","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2023.101736","article-title":"Vedolizumab does not increase risk of clostridium difficile infection in patients with inflammatory bowel disease using vedolizumab: A retrospective cohort study","volume":"31","author":"Saad Alshahrani","year":"2023","journal-title":"Saudi Pharm J"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4103\/sjg.sjg_118_24","article-title":"Association between vedolizumab and risk of clostridium difficile infection in patients with ulcerative colitis: A systematic review and meta-analysis","volume":"30","author":"Alghamdi","year":"2024","journal-title":"Saudi J Gastroenterol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2024.2345383","article-title":"Acute interstitial nephritis in patients with inflammatory bowel disease treated with vedolizumab: a systematic review","volume":"59","author":"Forss","year":"2024","journal-title":"Scand J Gastroenterol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1684476","article-title":"Case report: Severe kidney involvement in a case of very early onset inflammatory bowel disease","volume":"16","author":"Drago","year":"2025","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1159\/000511644","article-title":"Vedolizumab-induced liver injury","volume":"28","author":"Mascarenhas Saraiva","year":"2021","journal-title":"GE Port J Gastroenterol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1159\/000525404","article-title":"Acute chest pain as an infusion reaction to vedolizumab","volume":"16","author":"Levartovsky","year":"2022","journal-title":"Case Rep Gastroenterol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1201\/b14283-52","article-title":"Long-term safety of vedolizumab for inflammatory bowel disease","volume":"52","author":"Loftus","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000140","article-title":"A high prevalence of gastrointestinal manifestations in common variable immunodeficiency","volume":"114","author":"Pikkarainen","year":"2019","journal-title":"Am J Gastroenterol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1953966\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:36:52Z","timestamp":1791175012000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1953966\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2026.1953966"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1953966","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"article-number":"1953966"}}